Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92,475 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE, Ellis MJ, Alley HM, Eisele K, VanArsdale T, Dann SG, Arndt KT, Primeau T, Griffin E, Shao J, Crowder R, Lai JP, Norris JD, McDonnell DP, Li S. Wardell SE, et al. Among authors: li s. Clin Cancer Res. 2015 Nov 15;21(22):5121-5130. doi: 10.1158/1078-0432.CCR-15-0360. Epub 2015 May 19. Clin Cancer Res. 2015. PMID: 25991817 Free PMC article.
Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer.
Bai L, Zhou B, Yang CY, Ji J, McEachern D, Przybranowski S, Jiang H, Hu J, Xu F, Zhao Y, Liu L, Fernandez-Salas E, Xu J, Dou Y, Wen B, Sun D, Meagher J, Stuckey J, Hayes DF, Li S, Ellis MJ, Wang S. Bai L, et al. Among authors: li s. Cancer Res. 2017 May 1;77(9):2476-2487. doi: 10.1158/0008-5472.CAN-16-2622. Epub 2017 Feb 16. Cancer Res. 2017. PMID: 28209615 Free PMC article.
Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers.
Mundt F, Rajput S, Li S, Ruggles KV, Mooradian AD, Mertins P, Gillette MA, Krug K, Guo Z, Hoog J, Erdmann-Gilmore P, Primeau T, Huang S, Edwards DP, Wang X, Wang X, Kawaler E, Mani DR, Clauser KR, Gao F, Luo J, Davies SR, Johnson GL, Huang KL, Yoon CJ, Ding L, Fenyö D, Ellis MJ, Townsend RR, Held JM, Carr SA, Ma CX. Mundt F, et al. Among authors: li s. Cancer Res. 2018 May 15;78(10):2732-2746. doi: 10.1158/0008-5472.CAN-17-1990. Epub 2018 Feb 22. Cancer Res. 2018. PMID: 29472518 Free PMC article.
Assessment of Copper Nanoclusters for Accurate in Vivo Tumor Imaging and Potential for Translation.
Heo GS, Zhao Y, Sultan D, Zhang X, Detering L, Luehmann HP, Zhang X, Li R, Choksi A, Sharp S, Levingston S, Primeau T, Reichert DE, Sun G, Razani B, Li S, Weilbaecher KN, Dehdashti F, Wooley KL, Liu Y. Heo GS, et al. Among authors: li s, li r. ACS Appl Mater Interfaces. 2019 Jun 5;11(22):19669-19678. doi: 10.1021/acsami.8b22752. Epub 2019 May 22. ACS Appl Mater Interfaces. 2019. PMID: 31074257 Free PMC article.
Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.
Gou X, Anurag M, Lei JT, Kim BJ, Singh P, Seker S, Fandino D, Han A, Rehman S, Hu J, Korchina V, Doddapaneni H, Dobrolecki LE, Mitsiades N, Lewis MT, Welm AL, Li S, Lee AV, Robinson DR, Foulds CE, Ellis MJ. Gou X, et al. Among authors: li s. Cancer Res. 2021 Dec 15;81(24):6259-6272. doi: 10.1158/0008-5472.CAN-21-1256. Epub 2021 Oct 28. Cancer Res. 2021. PMID: 34711608 Free PMC article.
Crizotinib induces Par-4 secretion from normal cells and GRP78 expression on the cancer cell surface for selective tumor growth inhibition.
Burikhanov R, Ganguly S, Ellingson S, Sviripa VM, Araujo N, Li S, Venkatraman P, Rao M, Choughule A, Brainson CF, Zhan CG, Spielmann HP, Watt DS, Govindan R, Rangnekar VM. Burikhanov R, et al. Among authors: li s. Am J Cancer Res. 2023 Mar 15;13(3):976-991. eCollection 2023. Am J Cancer Res. 2023. PMID: 37034206 Free PMC article.
92,475 results
You have reached the last available page of results. Please see the User Guide for more information.